US 12,466,879 B2
Complement factor D antagonist antibodies and conjugates thereof
Daniel Victor Perlroth, Palo Alto, CA (US); Wah Yuen To, San Mateo, CA (US); Hong Liang, Hillsborough, CA (US); Rachel Marie DeVay Jacobson, Belmont, CA (US); and Fernando Corrêa, Hayward, CA (US)
Assigned to KODIAK SCIENCES INC., Palo Alto, CA (US)
Filed by KODIAK SCIENCES INC., Palo Alto, CA (US)
Filed on Feb. 6, 2023, as Appl. No. 18/165,233.
Application 18/165,233 is a division of application No. 15/952,092, filed on Apr. 12, 2018, granted, now 11,584,790.
Claims priority of provisional application 62/485,718, filed on Apr. 14, 2017.
Prior Publication US 2023/0382983 A1, Nov. 30, 2023
Int. Cl. C07K 16/18 (2006.01); A61K 47/68 (2017.01); C07K 14/47 (2006.01); C07K 16/40 (2006.01)
CPC C07K 16/18 (2013.01) [A61K 47/6843 (2017.08); A61K 47/6885 (2017.08); C07K 16/40 (2013.01); C07K 14/472 (2013.01); C07K 2317/24 (2013.01); C07K 2317/33 (2013.01); C07K 2317/34 (2013.01); C07K 2317/41 (2013.01); C07K 2317/51 (2013.01); C07K 2317/515 (2013.01); C07K 2317/55 (2013.01); C07K 2317/565 (2013.01); C07K 2317/734 (2013.01); C07K 2317/76 (2013.01); C07K 2317/92 (2013.01); C07K 2317/94 (2013.01); C12Y 304/21046 (2013.01)] 22 Claims
 
1. A conjugate comprising:
an isolated antagonistic antibody that binds to complement factor D (CFD), the antibody comprising:
a CDRH1 that is the CDRH1 in SEQ ID NO: 520;
a CDRH2 that is the CDRH2 in SEQ ID NO: 520;
a CDRH3 that is the CDRH3 in SEQ ID NO: 520;
a CDRL1 that is the CDRL1 in SEQ ID NO: 525;
a CDRL2 that is the CDRL2 in SEQ ID NO: 525;
a CDRL3 that is the CDRL3 in SEQ ID NO: 525;
at least one of the following mutations (EU numbering): L234A, L235A, and G237A; and
at least one of the following mutations (EU numbering): Q347C or L443C; and
a polymer, wherein the polymer is covalently attached to the antibody.